The petition urges the agency to do away with an “unnecessary” and “burdensome” regulatory framework that significantly limits access to this medication.

As the Food and Drug Administration undertakes a full agency review of the safety of the chemical abortion drug mifepristone, four pro-abortion attorneys general are asking the FDA to reverse course and lift all remaining restrictions on the drug.